# Waters (WAT) Financial Model Free Excel 3-statement financial model and company analysis for Waters. - Canonical: https://finamodel.com/companies/waters - Industry: Laboratory Equipment - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/WAT.xlsx ## Model Purpose This model evaluates the equity valuation and credit profile of Waters Corporation, specifically allowing an analyst to assess the accretion and leverage impact of the transformative Reverse Morris Trust merger with Becton Dickinson's Biosciences & Diagnostic Solutions business. ## Company Overview Waters Corporation designs, manufactures, sells, and services analytical instruments, primarily liquid chromatography and mass spectrometry systems. The company operates a razor and blade business model where instrument sales drive highly profitable, recurring revenue from precision chemistry consumables and service contracts. The business is divided into two operating segments: Waters (liquid chromatography, mass spectrometry, and consumables, representing approximately 89% of revenue) and TA (thermal analysis and rheometry, representing approximately 11% of revenue). Geographically, the company has a balanced global footprint across the Americas, Europe, and Asia, serving pharmaceutical, industrial, and academic end markets. Waters holds a top-tier competitive position in the life sciences tools sector, competing directly with Agilent Technologies, Thermo Fisher Scientific, and Danaher. Recently, the company has shifted from bolt-on acquisitions to transformational M&A. Following the $1.36 billion acquisition of Wyatt Technology in 2023, Waters announced a massive Reverse Morris Trust transaction in late 2025 to combine with BD's Biosciences & Diagnostic Solutions business, a deal that will double its total addressable market while adding significant debt and issuing new equity. ## Revenue Deep Dive ### Instruments - **Segment name**: Instruments - **Revenue driver formula**: Instrument Volume x Average Selling Price - **Historical growth rate**: Flat to low single digits (highly cyclical) - **Key growth levers and headwinds**: Driven by pharmaceutical capital expenditure cycles, new product cycles, and macroeconomic conditions in key regions like China. - **Pricing dynamics**: Highly competitive, negotiated pricing with volume discounts for large pharmaceutical accounts. - **Revenue recognition notes**: Recognised upfront upon transfer of control (shipment or delivery). - **Seasonality**: Q4 is historically the strongest quarter by a wide margin due to year-end budget flushes by corporate and academic customers. ### Chemistry (Consumables) - **Segment name**: Chemistry - **Revenue driver formula**: Total Instrument Installed Base x Chemistry Pull-Through per Instrument - **Historical growth rate**: Mid to high single digits (7-9%) - **Key growth levers and headwinds**: Driven by testing volumes, large molecule applications, and regulatory testing requirements (such as PFAS testing). - **Pricing dynamics**: High pricing power due to the proprietary nature of the consumables required for specific instruments. - **Revenue recognition notes**: Recognised upon shipment. - **Seasonality**: Relatively smooth throughout the year, providing stability against instrument cyclicality. ### Service - **Segment name**: Service - **Revenue driver formula**: Total Instrument Installed Base x Service Attachment Rate x Average Contract Value - **Historical growth rate**: Mid single digits (5-7%) - **Key growth levers and headwinds**: Driven by the aging of the installed base and the complexity of new instruments requiring vendor maintenance. - **Pricing dynamics**: Contractual, typically billed annually. - **Revenue recognition notes**: Deferred revenue is recorded upfront and recognised rateably over the contract term. - **Seasonality**: Cash flow is seasonal based on contract renewal dates, but revenue recognition is smoothed. ## Cost Structure ### Variable Costs / COGS - **Line-by-line breakdown**: Manufacturing direct labour, raw materials, component costs, freight, and manufacturing overhead. - **Gross margin range**: 58.5% to 60.0% over the last 5 years. - **Key input costs and commodity exposures**: Electronic components, specialised metals, and supply chain logistics costs. - **How COGS scales with revenue**: High operating leverage on chemistry and service revenue; instrument margins are lower and more variable. ### Operating Expenses - **R&D**: Typically 6% of revenue. It covers new instrument platform development and software enhancements (such as the Empower platform). - **SG&A**: Typically 22% to 23% of revenue. Heavily driven by the direct sales force headcount and marketing activities. - **Depreciation & Amortisation**: Approximately 3% to 4% of revenue, heavily skewed towards amortisation of acquired intangibles from recent M&A. - **Stock-Based Compensation**: Approximately 1.5% to 2.0% of revenue. - **Restructuring / one-time charges**: Infrequent historically, but expected to be material as the company integrates the BD Biosciences & Diagnostic Solutions business. ### Margin Profile - **Gross margin**: ~59.4% - **EBITDA margin**: ~33.0% to 35.0% - **Operating margin**: GAAP operating margin is ~28.0%, while adjusted non-GAAP operating margin is ~31.0%. - **Margin trend**: Stable to slightly expanding due to a favourable mix shift towards high-margin recurring revenue (chemistry and service). ## Balance Sheet Structure - **Total assets**: Approximately $3.5 billion prior to the BD transaction. - **Key asset categories**: Cash, accounts receivable, inventory, and a growing base of acquired intangibles. - **Goodwill & intangibles as % of total assets**: Approximately 45% to 50%, driven largely by the 2023 Wyatt Technology acquisition. - **Working capital profile**: - **Days Sales Outstanding (DSO)**: 60 to 70 days. - **Days Inventory Outstanding (DIO)**: 90 to 100 days. - **Days Payable Outstanding (DPO)**: 30 to 40 days. - **Net working capital as % of revenue**: Typically positive 15% to 20%. - **Is working capital positive or negative?**: Positive. The company requires working capital to fund inventory for its global supply chain. - **PP&E**: Manufacturing facilities (including column manufacturing in Taunton, Massachusetts), demonstration equipment, and tooling. - **Right-of-use assets / operating leases**: Material but manageable, representing global sales and service offices. ## Capital Expenditure & Investment - **Capex as % of revenue**: 3.0% to 4.0%. - **Maintenance capex vs. growth capex**: Approximately 60% maintenance and 40% growth (facility expansions). - **Major capex programmes underway or planned**: Expansion of precision chemistry manufacturing capacity. - **Capitalised software / development costs if material**: Minimal relative to total capex; most R&D is expensed as incurred. - **M&A pattern**: Transitioned from organic growth with small bolt-ons to transformational M&A (Wyatt Technology and the pending BD transaction). - **Typical acquisition multiple paid**: High teens to low twenties EBITDA multiples for high-growth life science assets. ## Debt & Capital Structure - **Total debt**: Approximately $1.5 billion pre-merger. - **Debt/EBITDA ratio**: Historically below 1.5x, but expected to rise to approximately 2.3x upon closing the BD transaction. - **Credit rating**: Investment grade. - **Key debt instruments**: Senior unsecured notes and a revolving credit facility. - **Maturity profile**: Staggered maturities over the next 5 to 10 years. - **Interest rate profile**: Predominantly fixed rate via senior notes. - **Covenants**: Standard leverage and interest coverage ratios. - **Share repurchase programme**: Historically active, but capital allocation will pivot towards debt paydown following the BD transaction. - **Dividend policy**: The company does not currently pay a regular dividend. ## Cash Flow Characteristics - **Operating cash flow conversion**: Consistently strong, typically 1.1x to 1.2x of Net Income. - **Free cash flow margin**: Approximately 25% of revenue. - **Major non-cash items that bridge net income to OCF**: Depreciation, amortisation of acquired intangibles, and stock-based compensation. - **Working capital cash flow impact**: Modest use of cash as the business grows. - **Capex intensity**: Low, allowing for massive free cash flow generation. - **Cash tax rate vs. GAAP effective tax rate**: Cash taxes are generally aligned with the GAAP effective tax rate of approximately 15.0%. ## Sheet Structure 1. **Assumptions**: Hardcoded drivers for macro variables, segment growth, margins, tax rates, and specific inputs for the BD transaction. 2. **Revenue Build**: Detailed buildup of revenue by product type (Instruments, Chemistry, Service) and cross-checked by operating segment (Waters, TA). 3. **Income Statement**: GAAP and Non-GAAP views, clearly separating amortisation of acquired intangibles and restructuring costs. 4. **Working Capital**: Schedules for accounts receivable, inventory, accounts payable, and deferred revenue based on days outstanding metrics. 5. **PP&E & Intangibles**: Capex, depreciation waterfall, and amortisation schedules for Wyatt and BD intangibles. 6. **Debt Schedule**: Pre-merger debt tranches, the new $4.0 billion SpinCo debt assumption, interest expense calculations, and mandatory paydowns. 7. **M&A Pro-Forma**: A dedicated sheet modelling the Reverse Morris Trust transaction, including the 60.7 million share issuance, debt assumption, and consolidated financials. 8. **Cash Flow Statement**: Indirect method reconciling net income to ending cash. 9. **Balance Sheet**: Standard format balancing via the revolving credit facility or excess cash. 10. **Valuation**: Unlevered free cash flow build, WACC calculation, and DCF output. ## Key Financial Relationships 1. "Total Revenue = Instruments Revenue + Chemistry Revenue + Service Revenue" 2. "Instruments Revenue = Prior Year Instruments Revenue x (1 + Instrument Growth Rate)" 3. "Chemistry Revenue = Prior Year Chemistry Revenue x (1 + Chemistry Growth Rate)" 4. "Service Revenue = Prior Year Service Revenue x (1 + Service Growth Rate)" 5. "Gross Profit = Total Revenue - (Instruments COGS + Chemistry COGS + Service COGS)" 6. "Adjusted Operating Income = Gross Profit - R&D Expense - SG&A Expense" 7. "GAAP Operating Income = Adjusted Operating Income - Amortisation of Acquired Intangibles - Restructuring Charges" 8. "Pro-Forma Share Count = Current Shares Outstanding + 60.7 million" 9. "Pro-Forma Debt = Current Debt + 4000 million" 10. "Interest Expense = (Average Pre-Merger Debt x Pre-Merger Rate) + (Average SpinCo Debt x SpinCo Rate)" 11. "Deferred Revenue Ending Balance = Deferred Revenue Beginning Balance + New Service Billings - Recognised Service Revenue" 12. "Free Cash Flow = Operating Cash Flow - Capital Expenditures" ## Cross-Sheet Dependencies The **Assumptions** sheet dictates the growth rates and margin profiles on the **Revenue Build** and **Income Statement** sheets. The **M&A Pro-Forma** sheet is critical; it feeds the **Revenue Build** (adding BD segment revenue), the **Debt Schedule** (adding $4.0 billion in assumed debt), and the **Valuation** sheet (adjusting the share count). The **Income Statement** generates net income, which flows to the **Cash Flow Statement**. The **Cash Flow Statement** determines the ending cash balance, which flows to the **Balance Sheet**. A circularity exists between the **Debt Schedule**, **Income Statement**, and **Cash Flow Statement** because interest expense reduces net income, which reduces cash, which may trigger a revolver draw, thereby increasing interest expense. ## Sign Convention - Revenue, Assets, and Equity are positive. - Expenses (COGS, SG&A, R&D, Interest, Taxes) are negative on the Income Statement. - Cash outflows (Capital Expenditures, Debt Repayments, Share Repurchases) are negative on the Cash Flow Statement. - Liabilities are positive on the Balance Sheet. ## Things Most Likely to Go Wrong - Failing to accurately model the share issuance for the BD transaction; the model must add exactly 60,737,462 shares to the denominator for EPS calculations. - Ignoring the $4.0 billion debt assumption from the BD transaction, which will drastically alter the interest expense profile. - Mismodelling the mix shift; chemistry and service revenues carry significantly higher gross margins than instruments, so a faster growth rate in recurring revenue must drive gross margin expansion. - Confusing GAAP and Non-GAAP operating margins; excluding acquisition-related amortisation flatters the adjusted margin by several hundred basis points. - Overestimating instrument growth during pharmaceutical capital expenditure downcycles. - Failing to account for foreign exchange impacts, which can swing reported revenue by 3% to 5% year-over-year. - Miscalculating the deferred revenue release schedule, which is a leading indicator for service revenue growth. - Overlooking the $733 million termination fee risk associated with the BD transaction if regulatory hurdles are not cleared. ## Validation Checks - "Gross margin must remain between 58.5% and 60.0% based on historical stability; flag if outside this band." - "Adjusted operating margin should be approximately 31.0%." - "Free cash flow margin must be around 25% of revenue." - "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." - "Pro-forma share count must increase by exactly 60.7 million shares upon BD deal close." - "Pro-forma debt must increase by at least $4.0 billion upon BD deal close." - "OCF to Net Income conversion should exceed 1.0x." - "Debt/EBITDA should peak around 2.3x immediately following the BD transaction close." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Instrument Revenue Growth | 2.0 | % | Reflects cyclical recovery in pharma capex | | Chemistry Revenue Growth | 7.0 | % | Driven by testing volumes and large molecule adoption | | Service Revenue Growth | 6.0 | % | Driven by installed base expansion and price increases | | Gross Margin | 59.4 | % | Actual 2024 reported gross margin | | R&D as % of Revenue | 6.0 | % | Historical average required to maintain product leadership | | SG&A as % of Revenue | 22.5 | % | Historical average reflecting direct sales force costs | | Effective Tax Rate | 15.0 | % | Historical GAAP effective tax rate | | Capex as % of Revenue | 3.5 | % | Historical average for maintenance and capacity expansion | | Days Sales Outstanding (DSO) | 65 | Days | Based on historical accounts receivable turnover | | Days Inventory Outstanding (DIO) | 95 | Days | Based on historical inventory management | | Days Payable Outstanding (DPO) | 35 | Days | Based on historical supplier payment terms | | BD Deal Share Issuance | 60.7 | Millions | Stated share issuance for the Reverse Morris Trust transaction | | BD Deal Debt Assumption | 4000 | $ Millions | Stated SpinCo debt to be assumed by Waters | | WACC | 8.5 | % | Standard discount rate for life science tools peers | | Terminal Growth Rate | 3.0 | % | Long-term growth rate of the end markets | ## Data Sources & Benchmarks - **Filings**: SEC EDGAR for Waters Corporation (WAT) 10-K, 10-Q, and 8-K filings. - **Presentations**: Waters Investor Relations website for the 2025 Investor Day presentation and Q4 2024 earnings materials. - **Peers**: Agilent Technologies (A), Thermo Fisher Scientific (TMO), and Danaher Corporation (DHR) for margin and valuation benchmarking. - **Industry Data**: SDi (Strategic Directions International) for analytical instrument market share and growth data. ## Sources - Waters Corporation 2024 Annual Report on Form 10-K. - Waters Corporation Q4 2024 Earnings Press Release. - Waters Corporation 2025 Investor Day Presentation. - SEC 8-K filings detailing the Becton Dickinson Biosciences & Diagnostic Solutions Reverse Morris Trust transaction. - Financial data and consensus estimates from standard market data providers. --- ## Frequently asked questions ### What is Waters Corporation's primary business model and how does it generate revenue? Waters Corporation designs, manufactures, sells, and services analytical instruments, primarily liquid chromatography and mass spectrometry systems. The company operates a "razor and blade" business model, where instrument sales drive highly profitable, recurring revenue from precision chemistry consumables and service contracts. ### What are the main segments contributing to Waters Corporation's revenue? Waters Corporation's revenue is primarily driven by two operating segments: Waters, which accounts for approximately 89% of revenue from liquid chromatography, mass spectrometry, and consumables, and TA, contributing about 11% from thermal analysis and rheometry. The company serves pharmaceutical, industrial, and academic end markets globally. ### What is Waters Corporation's typical capital expenditure as a percentage of revenue? Waters Corporation's capital expenditure typically ranges from 3.0% to 4.0% of revenue. Approximately 60% of this is for maintenance, while 40% is allocated to growth initiatives like facility expansions, including precision chemistry manufacturing capacity. ### What are the key revenue growth and profitability assumptions used in the Waters Corporation financial model? The financial model for Waters Corporation assumes a Revenue Growth rate of approximately 5.28%. Key profitability assumptions include COGS as 9.64% of Revenue, R&D as 5.96% of Revenue, and SGA as 23.03% of Revenue. ### How does the Waters Corporation financial model assess equity valuation and credit profile? The Waters Corporation financial model is designed to evaluate the company's equity valuation and credit profile. It specifically allows an analyst to assess the accretion and leverage impact of the transformative Reverse Morris Trust merger with Becton Dickinson's Biosciences & Diagnostic Solutions business. ### Can I download an Excel financial model for Waters Corporation, and what is its forecast horizon? Yes, an Excel financial model for Waters Corporation is available for download. This general corporate model provides a forecast horizon spanning from FY2026 through FY2030. [Interactive forecast calculator](https://finamodel.com/companies/waters/forecast)